title: Statin drug use is not associated with prostate cancer risk in men who are regularly screened.
abstract: OBJECTIVE
  Prospective cohort studies support the hypothesis that statin drug users have a lower risk of aggressive prostate cancer. Whether statin drug use influences the risk of screen detected disease is less clear, possibly because of complex detection biases. Thus, we investigated this association in a setting in which men had low baseline serum prostate specific antigen concentration and were screened annually.
  
  
  METHODS
  We performed a cohort study of 9,457 men 55 years old or older at randomization to the placebo arm of PCPT (Prostate Cancer Prevention Trial). The men reported new use of medications quarterly. We estimated the multivariable adjusted HR of prostate cancer (574 cases in 62,192 person-years) for statin drug use and duration of use during the trial using Cox proportional hazards regression.
  
  
  RESULTS
  During 7 years of followup statin drug use during the trial was not associated with the risk of total prostate cancer (HR 1.03, 95% CI 0.82-1.30), or lower grade (HR 0.96, 95% CI 0.71-1.29) or higher grade (HR 1.27, 95% CI 0.85-1.90) prostate cancer. Duration of use during followup was also not associated with the risk of total, or lower or higher grade disease (p trend=0.7, 0.5 and 0.2, respectively).
  
  
  CONCLUSIONS
  These prospective results do not support the hypothesis that statin drugs protect against prostate cancer in the setting of regular prostate cancer screening.
authors: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins School of Medicine and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. Electronic address: eplatz@jhu.edu.
authors: Elizabeth A
authors: EA
authors: Platz
authors: SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington.
authors: Catherine M
authors: CM
authors: Tangen
authors: SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington.
authors: Phyllis J
authors: PJ
authors: Goodman
authors: SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington.
authors: Cathee
authors: C
authors: Till
authors: Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland.
authors: Howard L
authors: HL
authors: Parnes
authors: Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland.
authors: William D
authors: WD
authors: Figg
authors: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland.
authors: Demetrius
authors: D
authors: Albanes
authors: Cancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
authors: Marian L
authors: ML
authors: Neuhouser
authors: Center for Clinical and Translational Research, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio.
authors: Eric A
authors: EA
authors: Klein
authors: University of Colorado Denver School of Medicine, Aurora, Colorado.
authors: M Scott
authors: MS
authors: Lucia
authors: Department of Urology, University of Texas Health Sciences Center San Antonio, San Antonio, Texas.
authors: Ian M
authors: IM
authors: Thompson
authors: Cancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
authors: Alan R
authors: AR
authors: Kristal
mesh_terms: D015331:Cohort Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000139:chemically induced* / Q000453:epidemiology*; D018570:Risk Assessment
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017430:Prostate-Specific Antigen
keywords: hydroxymethylglutaryl-coA reductase inhibitors; mass screening; prostate; prostatic neoplasms; risk